Description
A synthetic 44-amino acid analogue of GHRH (Growth Hormone Releasing Hormone) with trans-3-hexenoic acid conjugated to N-terminus for increased stability. FDA-approved (Egrifta SV) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also studied for cognitive decline (Alzheimer’s).
Benefits:
Significant reduction of visceral adipose tissue (VAT – primary approved indication); improved lipid profiles (reduced triglycerides); potential cognitive improvement in MCI/early Alzheimer’s (ongoing trials); lean mass preservation; improved body composition; physiological GH stimulation pattern
Side Effects:
Joint pain / arthralgia (common); peripheral edema; myalgia / muscle aches; carpal tunnel syndrome (elevated GH); glucose intolerance / insulin resistance; injection site reactions (erythema, pruritis); increased IGF-1 (theoretical long-term cancer risk with chronic elevation)
For laboratory research only — not for human consumption.
Reviews
There are no reviews yet.